阿昔莫司膠囊聯合絞股藍總甙片治療以甘油三酯升高為主的混合型高脂血癥的療效觀察

禹振霞

【摘要】 目的 觀察阿昔莫司膠囊聯合絞股藍總甙片治療以甘油三酯升高為主的混合型高脂血癥的療效。方法 36例以甘油三酯升高為主的混合型高脂血癥患者， 隨機分成治療組及對照組， 各18例。治療組應用阿昔莫司膠囊聯合絞股藍總甙片治療， 對照組應用辛伐他汀片治療。觀察比較兩組治療效果及不良反應發生情況。結果 治療前， 兩組患者的甘油三酯、 總膽固醇、 低密度脂蛋白膽固醇比較， 差異均無統計學意義（t=0.177、0.033、0.309， P>0.05）；治療后， 治療組的甘油三酯低于對照組， 差異具有統計學意義 （t=2.949， P<0.05） ；兩組患者的總膽固醇及低密度脂蛋白膽固醇比較， 差異均無統計學意義（t=0.244、0.315， P>0.05）。治療后， 治療組2型糖尿病患者的空腹血糖（6.5±1.4）mmol/L低于對照組2型糖尿病患者（8.0±1.7）mmol/L， 差異具有統計學意義（P<0.05）。治療組無一例發生不良反應， 對照組發生1例（5.6%）， 兩組比較差異無統計學意義（P>0.05）。結論 阿昔莫司膠囊聯合絞股藍總甙片治療以甘油三酯升高為主的混合型高脂血癥療效確切， 并使糖尿病合并混合型高脂血癥患者的血糖降低。

【關鍵詞】 阿昔莫司膠囊；絞股藍總甙片；混合型高脂血癥

DOI：10.14163/j.cnki.11-5547/r.2017.02.046

Observation on curative effect of acipimox capsules combined with Jiaogulanzongdai tablets for the treatment of mixed hyperlipaemia mainly on elevated triglycerides YU Zhen-xia. Beijing City Daxing District Huangcun Hospital， Beijing 102600， China

【Abstract】 Objective To observe the curative effect of acipimox capsules combined with Jiaogulanzongdai tablets for the treatment of mixed hyperlipaemia mainly on elevated triglycerides. Methods A total of 36 patients with mixed hyperlipaemia mainly on elevated triglycerides were randomly divided into treatment group and control group， with 18 cases in each group. The treatment group received acipimox capsules combined with Jiaogulanzongdai tablets for treatment， and the control group received simvastatin tablets for treatment. Treatment effect was observed and compared in two groups. Results There were no statistically significant difference in triglyceride， total cholesterol and low-density lipoprotein cholesterol before treatment in two groups （t=0.177， 0.033， 0.309， P>0.05）. After treatment， the treatment group had lower triglyceride than that in the control group， and the difference had statistical significance （t=2.949， P<0.05）. There were no statistically significant difference in total cholesterol and low-density lipoprotein cholesterol in two groups （t=0.244， 0.315， P>0.05）. After treatment， the treatment group had lower fasting blood-glucose in type 2 diabetes mellitus patients as （6.5±1.4） mmol/L than （8.0±1.7） mmol/L in the control group， and the difference had statistical significance （P<0.05）. The treatment group had 0 adverse reaction case， while the control group had 1 adverse reaction case， and their difference had no statistical significance （P>0.05）. Conclusion Combined treatment of acipimox capsules and Jiaogulanzongdai tablets shows affirmative curative effect for the treatment of mixed hyperlipaemia mainly on elevated triglycerides. It also lower blood glucose of patients with diabetes complicated with mixed hyperlipidemia.